IFNAR1 and systemic lupus erythematosus: Finally, we observed suppression of the type I IFNPS following IFN alpha receptor (IFNAR) neutralisation in MUSE (NCT01438489), a phase IIb study of anifrolumab in moderate to severe SLE, demonstrating specificity of IFNPS for the type I IFN pathway6.